Company Overview
Snapshot
Founded in January 2009, HQL Pharmaceuticals operates with 1–10 employees. The company has secured $2.5M in total capital across one funding round, focusing on transforming drug discovery through computational methods. HQL Pharmaceuticals entered into a strategic alliance with Viva Biotech Ltd of Shanghai, China, in 2014 to jointly provide drug discovery services.
Business overview
HQL Pharmaceuticals is dedicated to transforming drug discovery into a highly efficient, computationally driven process. The company's core technology, the ChemSpace Scanner (CSS) computational platform, combines multiple drug design algorithms to screen vast chemical libraries against high-resolution models. This platform aims to generate diverse, high-quality drug candidates and address complex challenges in drug development, such as scaffold hopping and targeting protein-protein interactions. HQL Pharmaceuticals serves the pharmaceutical and biotechnology industries, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Log in to access full profile ›Company Intelligence Q&A
- What is HQL Pharmaceuticals' primary mission?
- HQL Pharmaceuticals' mission is to transform drug discovery into a computationally driven, highly efficient process, yielding a large diversity of high-quality drug candidates.
- What is the ChemSpace Scanner (CSS) platform?
- The ChemSpace Scanner (CSS) is HQL Pharmaceuticals' computational platform that enables the combination of multiple drug design algorithms to screen vast chemical libraries against high-resolution drug models, scoring and ranking resulting hits.
- When was HQL Pharmaceuticals founded?
- HQL Pharmaceuticals was founded in January 2009.
- What strategic alliance did HQL Pharmaceuticals form?
- In 2014, HQL Pharmaceuticals and Viva Biotech Ltd of Shanghai, China, entered into a strategic alliance to jointly provide drug discovery services.
- What challenges does HQL Pharmaceuticals' technology address?
- HQL Pharmaceuticals' technology addresses challenges associated with scaffold hopping, antagonizing protein-protein interactions, hitting two targets simultaneously, and transforming fragment hits into viable drug candidates.